Andra AP fonden Lowers Stock Holdings in UiPath Inc. (NYSE:PATH)

Andra AP fonden cut its holdings in UiPath Inc. (NYSE:PATH) by 8.5% in the 2nd quarter, HoldingsChannel reports. The fund owned 204,000 shares of the healthcare company’s stock after selling 19,000 shares during the period. Andra AP fonden’s holdings in UiPath were worth $2,587,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of UiPath in the fourth quarter worth approximately $25,000. ORG Partners LLC raised its stake in UiPath by 875.6% during the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock worth $27,000 after purchasing an additional 1,112 shares during the period. Lindbrook Capital LLC boosted its holdings in shares of UiPath by 46.0% in the 1st quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock valued at $46,000 after purchasing an additional 639 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of UiPath by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock valued at $50,000 after buying an additional 632 shares during the period. Finally, Hantz Financial Services Inc. acquired a new stake in shares of UiPath during the 2nd quarter worth $28,000. Hedge funds and other institutional investors own 62.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PATH. BMO Capital Markets boosted their price target on UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a research report on Friday, September 6th. JPMorgan Chase & Co. decreased their target price on UiPath from $28.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. Scotiabank cut their price target on shares of UiPath from $30.00 to $25.00 and set a “sector perform” rating on the stock in a report on Wednesday, May 29th. DA Davidson boosted their price objective on shares of UiPath from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Friday, September 6th. Finally, TD Cowen cut their target price on shares of UiPath from $17.00 to $16.00 and set a “hold” rating on the stock in a research note on Friday, September 6th. Sixteen analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $17.71.

UiPath Stock Down 0.1 %

Shares of PATH opened at $12.01 on Friday. The firm has a market cap of $6.88 billion, a price-to-earnings ratio of -75.03 and a beta of 0.87. The business’s 50 day moving average is $12.13 and its two-hundred day moving average is $16.40. UiPath Inc. has a 52-week low of $10.37 and a 52-week high of $27.87.

UiPath (NYSE:PATH) last posted its quarterly earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The firm had revenue of $316.00 million for the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.89%. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.09) earnings per share. On average, equities analysts expect that UiPath Inc. will post -0.22 earnings per share for the current fiscal year.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.